🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› EU
Clinical trial register · European Union · CTIS

Recently authorised EU trials

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12445 total CTIS records — a stated recency window, not the full historical archive. Synced 19 Sep 2026, 04:26 UTC
2500
Shown in this register
most recently authorised
12,445
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524
Narrow the registerReset
Phase
Phase I 558 Phase I/II 214 Phase II 726 Phase III 745 Phase IV 257
Lead sponsor
AstraZeneca AB 60 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 45 Novo Nordisk A/S 42
Member state
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524 Belgium 426 Czechia 327
All 28 states
257 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase IV
Randomized Evaluation of fleCAinide safety vs. STandard of care in patients with coronary artery disease and Atrial Fibrillation (ReCAST AF).
2025-525121-13-00Coronary artery disease, Atrial fibrillation
UZ Leuven
Cardiovascular Diseases
Belgium
26/06/2026
Phase IV
Prospective, multicenter, randomized study on combined LT4 + LT3 therapy versus LT4 in the control of TSH in patients with advanced thyroid cancer treated with tyrosine kinase inhibitors.
2026-526113-28-00Advanced thyroid carcinoma. Post-thyroidectomy hypothyroidi…
Ceinge Biotecnologie Avanzate Franco Salvatore S.c.a.r.l.
Hormonal diseases
Italy
26/06/2026
Phase IV
Short and long-term Hemodynamic and Physiological Effects of Mavacamten in Obstructive Hypertrophic Cardiomyopathy
2025-524722-17-00Obstructive Hypertrophic Cardiomyopathy
Region Skane
Cardiovascular Diseases
Sweden
26/06/2026
Phase IV
Phase IV study evaluating the efficacy and safety of the venetoclax + rituximab (VR) regimen in patients with relapsed chronic lymphocytic leukemia in Polish clinical practice
2025-524795-35-00Adult with chronic lymphocytic leukemia/small lymphocytic l…
Uniwersytet Medyczny W Lublinie
Hemic and Lymphatic Diseases
Poland
26/06/2026
Phase IV
A multicentre, adaptive, randomised, multidomain, platform trial for dose optimization in the treatment of adult patients with haematological diseases (BLOOD-dose): core protocol
2026-525658-13-00Haematological diseases; any disorder that primarily affect…
Region Hovedstaden
Hemic and Lymphatic Diseases
Denmark
25/06/2026
Phase IV
ECETEP : Pilot study evaluating PSMA positron emission tomography for monitoring clinically significant prostate cancer after focal HIFU treatment
2026-525181-22-00prostate cancer
Centre Hospitalier Universitaire De Toulouse
Diagnosis
France
25/06/2026
Phase IV
Morphine for resting breathlessness in severe illness and palliative care (MORE-B): a randomized clinical trial
2026-525838-32-00Serious, chronic, life-limiting disease
Region Skane
Respiratory Tract Diseases
Sweden
24/06/2026
Phase IV
The impact of ovarian stimulation with hMG on embryo quality in advanced age women. A randomized controlled trial
2025-524761-25-00infertility
Santiago Dexeus Font Fundacio Privada
Female Urogenital Diseases and Pregnancy Complications
Spain
23/06/2026
Phase IV
USEFULNESS OF HIGH-FLOW OXYGEN THERAPY TO IMPROVE THE SAFETY OF PATIENTS AT HIGH RISK OF HYPOXEMIA UNDERGOING DIGESTIVE ENDOSCOPY UNDER DEEP SEDATION: A RANDOMIZED MULTICENTER COMPARATIVE STUDY. THE ENDOALF-TRIAL.
2026-525766-21-01Hypoxemic episodes in patients undergoing gastroscopy, colo…
Hospital Universitario Rio Hortega
Respiratory Tract Diseases
Spain
23/06/2026
Phase IV
Treatment strategies for juvenile idiopathic arthritis patients with sustained inactive disease: A phase 4, multicentre, randomised trial comparing maintenance versus tapered TNF alpha inhibitor monotherapy - the Treat-JIA trial
2026-525611-13-00Juvenil Idiopatic Arthritis
Oslo Universitetssykehus HF
Musculoskeletal Diseases
Norway
23/06/2026
Phase IV
Sample Collection Study to Monitor the Risk of Malignancy Due to Insertional Oncogenesis in Early Onset Patients with Metachromatic Leukodystrophy Treated with OTL-200 in the Clinical Development Program
2025-522275-28-00Metachromatic leukodystrophy
Orchard Therapeutics (Europe) Limited
Musculoskeletal Diseases
Netherlands, Germany, Italy, Sweden, France
22/06/2026
Phase IV
Insulin resistance in type 2 diabetes: evaluating the pathogenic mechanisms of insulin resistance in the myocardium and the effects of the treatments with GLP-1RA and SGLT2i
2025-523374-17-03Type 2 diabetes
Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
Nutritional and Metabolic Diseases
Spain
19/06/2026
Phase IV
Tacrolimus as prophylaxis of post-ERCP pancreatitis: a DPSG (Dutch Pancreatitis Study Group) multicenter, double-blind, randomized, placebo-controlled study.
2025-522900-26-00Post-ERCP Pancreatitis
Amsterdam UMC Stichting
Digestive System Diseases
Netherlands
19/06/2026
Phase IV
STOP - Safety and efficacy of a STOPping strategy versus classical maintenance dose of JAK inhibitors in deep remission patients with ulcerative colitis: a randomized controlled trial
2026-525643-32-00ulcerative colitis
Centre Hospitalier Regional De Marseille
Digestive System Diseases
France
17/06/2026
Phase IV
Real-World Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy (C3G) or Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN): A Multi-Country Study (PRISMC3)
2025-524487-37-00C3 Glomerulopathy (C3G), Primary Immune Complex Membranopro…
Swedish Orphan Biovitrum AB (publ)
Immune System Diseases
France, Italy, Spain, Germany, Belgium
15/06/2026
Phase IV
BEAT Fatigue – Benefit of Elevated Administration of Thiamine for Fatigue in Rheumatoid Arthritis: A randomized, double-blind, placebo-controlled trial
2024-519268-41-00Fatigue in rheumatoid arthritis patients
Odense University Hospital
Musculoskeletal Diseases
Denmark
12/06/2026
Phase IV
Efficacy of top-down therapy with mirikizumab versus standard of care with azathioprine in patients with newly diagnosed, moderate-to-severe Crohn’s disease: A 52-week, multicenter, open-label, randomized controlled trial
2026-525191-26-00Crohn’s disease
Universitaetsklinikum Schleswig-Holstein AöR
Digestive System Diseases
Germany
11/06/2026
Phase IV
Clinical trial to evaluate the correlation between variation in intestinal lactase activity measured with LacTEST 0.45g and alteration of intestinal barrier integrity and/or intestinal permeability in patients with celiac disease
2026-525518-70-00Patients with celiac disease
Venter Pharma S.L.
Digestive System Diseases
Spain
11/06/2026
Phase IV
DISCO-RA:DIScontinuation of COncomitant disease modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis patients also using TNF inhibitors - a randomized long-term non-inferiority strategy trial
2026-525316-33-00Rheumatoid arthritis
Sint Maartenskliniek Stichting
Immune System Diseases
Netherlands
09/06/2026
Phase IV
A neuropsychobiological approach to optimize patient selection for GLP-1-based pharmacotherapy for weight management across the binge eating spectrum
2026-526016-36-00obesity
UZ Leuven
Nutritional and Metabolic Diseases
Belgium
08/06/2026
Phase IV
OCTAGON:A Phase 4, Single Arm Study to Investigate Oral Corticosteroid Tapering in Adult Patients with Generalized Myasthenia Gravis Treated with Ravulizumab
2025-522555-26-00Generalized Myasthenia Gravis
Alexion Pharmaceuticals Inc.
Nervous System Diseases
Italy, Germany
08/06/2026
Phase IV
PREP-ANCA - Comparison of a strategy based on clinic-biological surveillance versus pre-emptive treatment with rituximab in the event of ANCA (anti-neutrophil cytoplasm antibodies) repositivation in patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)
2025-522049-23-00granulomatosis with polyangiitis and microscopic polyangiit…
Assistance Publique Hopitaux De Paris
Immune System Diseases
France
08/06/2026
Phase IV
Measles-mumps-rubella vaccine (MMR) at 6 months of age: Long-term follow-up
2026-526160-21-00Prevention of measles, mumps, and rubella by vaccination
Rigshospitalet
Virus Diseases
Denmark
08/06/2026
Phase IV
ANTIMIDIS - Cefazolin mediastinal distribution using microdialysis
2025-521988-13-00Infection prophylaxis
Assistance Publique Hopitaux De Paris
Bacterial Infections and Mycoses
France
05/06/2026
Phase IV
BIOlogical treatment GRAdual Interval Longing in severe Asthma (BIO-GRAIL)
2025-524741-28-00Severe Asthma
Amsterdam UMC Stichting
Respiratory Tract Diseases
Netherlands
05/06/2026
Rows per page Showing 51–75 of 257
Previous 1 2 3 4 5 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 19 September 2026. https://priyalifescience.com/clinical-trials-europe

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.